Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in α-synuclein transgenic mice
- Margot Fournier†1, 4, 9,
- Amandine Roux†1, 2, 3,
- Jérôme Garrigue1, 2, 3,
- Marie-Paule Muriel1, 2, 3,
- Paul Blanche5,
- Hilal A Lashuel4,
- John P Anderson6,
- Robin Barbour6,
- Jiping Huang6,
- Sophie Tezenas du Montcel5, 7,
- Alexis Brice1, 2, 3, 8 and
- Olga Corti1, 2, 3Email author
© Fournier et al.; licensee BioMed Central Ltd. 2013
Received: 27 May 2013
Accepted: 28 October 2013
Published: 5 November 2013
Mutations of the gene encoding the major component of Lewy bodies (LB), α-synuclein (α-syn), cause autosomal dominant forms of Parkinson’s disease (PD), whereas loss-of-function mutations of the gene encoding the multifunctional E3 ubiquitin-protein ligase Parkin account for autosomal recessive forms of the disease. Parkin overproduction protects against α-syn-dependent neurodegeneration in various in vitro and in vivo models, but it remains unclear whether this process is affected by Parkin deficiency. We addressed this issue, by carrying out more detailed analyses of transgenic mice overproducing the A30P variant of human α-syn (hA30Pα-syn) and with two, one or no parkin knockout alleles.
Longitudinal behavioral follow-up of these mice indicated that Parkin depletion delayed disease-predictive sensorimotor impairment due to α-syn accumulation, in a dose-dependent fashion. At the end stage of the disease, neuronal deposits containing fibrillar α-syn species phosphorylated at S129 (PS129α-syn) were the predominant neuropathological feature in hA30Pα-syn mice, regardless of their parkin expression. Some of these deposits colocalized with the LB markers ubiquitin and α-syn truncated at D135 (α-synD135), indicating that PS129α-syn is subjected to secondary posttranslational modification (PTM); these features were not significantly affected by parkin dysfunction.
These findings suggest that Parkin deficiency acts as a protective modifier in α-syn-dependent neurodegeneration, without overtly affecting the composition and characteristics of α-syn deposits in end-stage disease.
Keywordsα-syn phosphorylation α-syn truncation Ubiquitin Posttranslational modifications Transgenic mice overproducing α-syn parkin knockout mice Parkinson’s disease
Biochemical studies of α-syn within Lewy bodies (LB) revealed various posttranslational modifications (PTM) of the protein, some of which are associated with Parkinson’s disease (PD) and other synucleinopathies (for a recent review on α-syn PTM, see ). The most abundant α-syn PTM is phosphorylation: nearly 90% of the molecules of this protein in LB are phosphorylated at S129 (PS129α-syn) [2, 3]. α-Syn is also ubiquitylated [2, 4–6]; various lysine residues affected by this PTM have been identified, mostly in the N-terminal part of the protein [2, 7, 8]. Ubiquitin has been shown to be primarily associated with PS129α-syn [2, 4, 5], raising the possibility of crosstalk between the two modifications. In addition, about 15% of α-syn is truncated in LB [9, 10] and various C-terminally cleaved α-syn species (e.g. D135, Y133, N122, D119, D115) have been identified [2, 4, 9–12]. All these α-syn species have been shown to accumulate in animal models of α-synucleinopathy [11, 13–24], but they have mostly been studied independently of each other. Thus, the interplay between them remains poorly understood.
Most early-onset autosomal recessive cases of PD are due to mutations in the gene encoding Parkin [25, 26], an E3 ubiquitin-protein ligase involved in the ubiquitylation of a number of substrates (e.g. CDCRel-1, Pael R, synphilin, p38/JTV1/AIMP2, Eps15) and in various cellular mechanisms, including signaling pathways, synaptic transmission, proteasomal protein degradation and the autophagy of dysfunctional mitochondria [25, 27]. It is unclear whether mutations in the α-syn and parkin genes converge into common neuropathological pathways. The overproduction of Parkin protects against α-syn-induced toxicity, both in vitro and in vivo[19, 28–30], but conflicting results have been reported in models of Parkin depletion, which mimics the loss of protein function underlying PD due to parkin mutations [16, 31].
We explored this issue further, in mice producing the pathogenic human A30P variant of α-syn (hA30Pα-syn). Transgenic hA30Pα-syn mice are a well described model of α-synucleinopathy, characterized by an age-dependent lethal movement disorder associated with the deposition of proteinase K-resistant α-syn, PS129α-syn and ubiquitin throughout the central nervous system [16, 21, 32]. We previously reported that Parkin deficiency due to biallelic gene knockout delays the onset of the neurodegenerative phenotype in this model . In this study, we used a set of behavioral tests to monitor the development of motor dysfunction in hA30Pα-syn mice with two, one or no functional parkin alleles. We also provide a detailed immunohistochemical description of the α-syn deposits, to clarify the relationships between the various PTM of the protein and the effects of an absence of Parkin. We report that dysfunctional parkin alleles delay the onset of disease signs, in a dose-dependent manner, in hA30Pα-syn mice, with only modest effects on neuropathological characteristics in end-stage disease.
All experiments involving mice were approved by the Ile-de-France Regional Ethics Committee for Animal Experiments, Nu3 (P3/2006/006). Post-mortem samples of PD patients were obtained from brains collected in a Brain Donation Program of the Brain Bank “GIE NeuroCEB”, run by a consortium of Patient Associations: ARSEP (association for research on multiple sclerosis), CSC (cerebellar ataxias), France Alzheimer and France Parkinson. Consents were signed by the patients or their next of kin in their name, in accordance with French bioethics law. The approval for the collection of samples in the Brain Bank has been granted by the Ministry of Higher Education and Research (authorization #AC 2007–5).
Experimental groups of female littermate mice were generated, genotyped and housed, as previously described . In brief, homozygous parkin knockout mice  brought into the C57Bl/6j genetic background by an accelerated backcross procedure were bred with homozygous hA30Pα-syn mice brought into a C57Bl/6j background by eight consecutive backcrosses . Mice of the double-heterozygous generation were then crossed to generate littermates of the nine expected genotypes. Age-matched littermates of the genotypes of interest were used for all subsequent analyses. Behavioral studies were performed in the mornings of two consecutive days, by investigators blind to genotype. The animals were weighed, and behavioral tasks were performed in the following order: 1) extension reflex, 2) rotarod test and 3) footprint test. The symmetry of the hindlimb extension reflex and the time spent on a rotating rod were studied as previously described . The amplitude of the extension reflex was characterized as follows: 5- swift and wide, 4- normal, 3- mild, 2- narrow, 1- little movement 0- no extension. On this scale, 3 was considered to correspond to an abnormally low score, because it was not observed in control groups; a score of 2 or 1 was invariably accompanied by an abnormal gait. For the footprint test, the hindpaws and forepaws were inked with different colors and the animal was placed at the entrance of a corridor (10 cm long x 5 cm wide x 5 cm high) covered with a paper sheet; the mouse was allowed to walk through without pause. Based on consecutive imprints, we measured the length and width of four steps for the forelimbs and hindlimbs.
Qualitative and quantitative immunofluorescence analyses
Three cases of sporadic PD and an age-matched control without neurological lesions were selected from the Escourolle Neuropathology Laboratory of Pitié-Salpêtrière Hospital. The PD cases were characterized histopathologically for neuron loss from the substantia nigra and for the presence of LB, as previously described . All histological immunofluorescence staining was performed as described by Vitte et al. , after bleaching to eliminate the autofluorescence of the human tissue, by incubating the sections in phosphate-buffered saline (PBS) for 2 h under the light of a desk lamp at 4°C. All immunohistochemical analyses in animals were performed in homozygous hA30Pα-syn+/+ mice with (parkin-/-) or without Parkin deficiency. Animals were killed in the end stage of the disease, about three weeks after the onset of symptoms, and the brain was removed and processed for immunohistochemistry, as previously described . For preabsorption experiments, an antibody directed against α-syn truncated at D135 (α-synD135) was first incubated for 6 h in PBS supplemented with 4% bovine serum albumin (BSA), 10% newborn goat serum (NGS) with the recombinant proteins of interest (α-synD135, α-synY133 and α-syn), at an antibody:protein ratio of 1:2000. The proportion of LB detected by PS129α-syn staining also displaying α-synD135 labeling was estimated on 50 LB from the three cases of PD. The percentage of cell bodies and processes costained for the different markers was quantified in two or three representative 5 μm-thick coronal brainstem sections selected on the basis of staining abundance and observed with an epifluorescence microscope (magnification x63, Axioplan 2, Zeiss, Germany). We scored about 50 neuronal cell bodies and 100 processes, identified on the basis of morphology and DAPI staining, for each animal, and six to ten animals from each genotype were analyzed. Brightfield images were acquired with a multipurpose zoom microscope (NIKON AZ100) and NIS software. Colocalization of different types of immunofluorescent labeling was further analyzed with a confocal microscope (Leica SP2 AOBS, Wetzlar, Germany) and a x63 objective. Z-stack images, with 0.2 μm Z-intervals covering entire immunostained volumes within individual cell bodies or processes (n = 6 structures), were taken from representative animals (n = 3) for each relevant genotype. The degree of colocalization was determined by calculating Pearson’s coefficient with the JACoP plug-in of ImageJ software.
Immunostaining for electron microscopy
Mice were anesthetized with pentobarbital (130 mg/kg, i.p.; Sigma, St Quentin, France) and perfused transcardially with 4% PFA freshly prepared in PBS supplemented with 0.01% glutaraldehyde. Brains were removed and post-fixed by incubation overnight in 4% PFA. Sections from the brainstem (45 μm thick), which has been show to contain abundant PS129α-syn deposits, were obtained with a vibratome (HM 650 V Microm International), immunolabeled for PS129α-syn and then incubated with 3,3'-diaminobenzidine (DAB) or gold . Ultrathin sections (60 nm) were analyzed with a JEOL 1200EX II electron microscope at 80 kV (Akishima, Japan).
Mouse monoclonal anti-α-synD135 and anti-α-synY133 antibodies were generated essentially as previously described , with the peptides CGGEEGYQD and CGGPSEEGY, the corresponding synuclein sequences with three-residue extensions at the N-terminal end for coupling, as immunogens. These peptides were coupled to sheep anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) with sulfo-EMCS (Molecular Biosciences, Boulder CO). Sera were then purified with Protein A-Sepharose and the antibodies were used at dilutions of 1:1000 (anti-α-synD135) or 1:700 (anti-α-synY133). We also used the following commercially available primary antibodies: rabbit polyclonal anti-ubiquitin (1:1000) from DAKO, rabbit monoclonal anti-PS129α-syn (1:2500 for electron microscopy, otherwise 1:5000) from Abcam; mouse monoclonal anti-PS129 α-syn (1:5000, WAKO); and rabbit polyclonal anti-full length α-syn (1:1000) from Affinity Biologicals. For immunohistochemistry, we used the following secondary antibodies: goat anti-rabbit or anti-mouse IgG conjugated to Alexa Fluor 488 (1:1000, Invitrogen), donkey anti-rabbit or anti-mouse IgG conjugated to Cy3 (1:500, Jackson).
Mass spectrometry analysis (MS)
Sodium dodecyl sulfate (SDS)-soluble brain fractions  were run on an SDS polyacrylamide (15%) gel, which was then stained with Coomassie blue. Gel pieces containing the proteins of interest were destained and desiccated by incubation twice, for 20 min each, in 200 μl of 50 mM ammonium bicarbonate, 50% ethanol. Samples were then dried, incubated with modified trypsin (12.5 ng/μl) overnight at 37°C and stored at -80°C. The digested peptides were resuspended in 20 μl of 0.75% trifluoroacetic acid (TFA), 60% acetonitrile, 300 mg/ml lactic acid (solution A), loaded onto home-made titanium tips , equilibrated with solution A and washed with solution A supplemented with 0.1% TFA and 80% acetonitrile (ACN). Samples were eluted twice with 0.5% ammonium hydroxide and 0.5% piperidine. Eluted fractions were acidified with formic acid (FA) and dried in a Speedvac. Peptides were resuspended in 2% ACN/0.1% FA for LC-MS/MS analysis (liquid chromatography - MS). MS analysis was performed on an LTQ Orbitrap XL (Thermo Fisher Scientific) equipped with a nanoACQUITY system (Waters). Tandem MS was carried out in an information-dependent mode, in which each full MS analysis was followed by three MS/MS acquisitions, with peptides selected for collision-induced dissociation (CID), to generate tandem mass spectra. The results of the data searches were imported into Scaffold (Version 3_00_8 Proteome Software) for the validation of protein identification. Mascot 2.3 (Matrix Science) and SEQUEST in Proteome Discoverer v.1.2 were used for data searches against a database for the human and mouse α-syn forms, and spectra were validated by manual inspection.
Production of recombinant proteins, in vitrophosphorylation assays and western blot analyses
Early stop codons were introduced into the sequence of wild-type α-syn, in the pT7.7 backbone, by single-site mutagenesis with complementary oligonucleotides (α-synD135, forward and reverse primers: gccttctgaggaagggtatcaagactaetaacctgaagcctaag, cttaggcttcaggttattagtcttgatacccttcctcagaaggc; α-synY133, forward and reverse primers: ctgaggaagggtattaatgactacgaacctgaagcctaag, cttaggcttcaggttcgtagtcattaatacccttcctcag). All constructs were verified by sequencing. The recombinant proteins were produced and phosphorylated by Polo-like kinase 3 (PLK3, Invitrogen) as previously described [37, 38]. Recombinant proteins were resolved by SDS-PAGE in 4-12% polyacrylamide gels, electrotransferred to nitrocellulose membranes and probed with anti-α-synD135 (1:400), anti-α-synY133 (1:400) or anti-α-syn (1:1000, Affiniti) antibodies. Antibody binding was visualized by incubation with secondary anti-rabbit IgG (1:50000, Jackson Laboratories) and enhanced chemiluminescence (West Pico Chemiluminescent substrate, Pierce or West Dura Extended Duration Substrate, Thermoscientific) with a Kodak Image J Station 4000 MM.
Symmetry of the hind limb extension reflex: wild-type = 0.03743.weight + 0.985 – 0.00239.age, hA30Pα-syn+/+ = 0.03743.weight + 1.0863 – 0.02742.age – 0.001548.age2 – 0.00003.age3, parkin+/-; hA30Pα-syn+/+ = 0.03743.weight + 0.9866 – 0.02692.age – 0.000889.age2 – 0.00001.age3, parkin-/-; hA30Pα-syn+/+ = 0.03743.weight + 1.0286 – 0.0143.age + 0.000664.age2 – 0.00000984.age3, parkin-/-; hA30Pα-syn+/- = 0.03743.weight + 0.9833, parkin-/- = 0.03743.weight + 1.0504.
Amplitude of the hind limb extension reflex: wild-type = 0.1311.weight + 0.8324 – 0.2131.age + 0.005619.age2 – 0.00005.age3, hA30Pα-syn+/+ = 0.1311.weight – 0.00003.age3, parkin+/-; hA30Pα-syn+/+ = 0.1311.weight – 0.00002.age3, parkin-/-; hA30Pα-syn+/+ = 0.1311.weight + 1.2297 – 0.05299.age + 0.00021.age2, parkin-/-; hA30Pα-syn+/- = 0.1311.weight + 0.9174, parkin-/- = 0.1311.weight + 1.3363 – 0.00021.age2.
Rotarod test: wild-type = 2.6585.weight + 110.04 – 1.41.age + 0.016.age2, hA30Pα-syn+/+ = 2.6585.weight + 138.88 – 5.42.age + 0.223.age2 – 0.00435.age3, parkin+/-; hA30Pα-syn+/+ = 2.6585.weight + 98.17 – 0.00108.age3, parkin-/-; hA30Pα-syn+/+ = 2.6585.weight + 112.46 – 0.00054.age3, parkin-/-; hA30Pα-syn+/- = 2.6585.weight + 107.98, parkin-/- = 2.6585.weight + 110.72.
Length of forelimb stride: wild-type = 0.5815.weight + 5.1139 – 0.00000832.age3, hA30Pα-syn+/+ = 0.5815.weight + 4.6383 + 0.004034.age2 – 0.00015.age3, parkin+/-; hA30Pα-syn+/+ = 0.5815.weight + 5.3843 – 0.1668.age + 0.01054.age2 – 0.00019.age3, parkin-/-; hA30Pα-syn+/+ = 0.5815.weight + 5.5677 – 0.03991.age, parkin-/-; hA30Pα-syn+/- = 0.5815.weight + 5.0679 parkin-/- = 0.5815.weight + 5.0634.
Parkin depletion delays the appearance of motor dysfunction in a dose-dependent manner in hA30Pα-syn mice
Age by which a 50% decrease in the mean test performance of each group had occurred, or a 25% decrease in the case of the footprint test, within a confidence interval of one week, determined from the mathematical models established
Amplitude of extension reflex score < 2.5
Rotarod time on rod < 90 s
Symmetry of extension reflex score < 1
Stride length < 5 cm
18.1 ± 0.2 months
19.3 ± 0.2 months
20.0 ± 0.2 months
20.7 ± 0.2 months
18.4 ± 0.2 months
20.2 ± 0.2 months
22.3 ± 0.2 months
23.0 ± 0.2 months
21.0 ± 0.2 months
23.2 ± 0.2 months
23.4 ± 0.2 months
> 24 months
Truncated α-syn species found in LB accumulate in symptomatic hA30Pα-syn mice in the presence and absence of Parkin
Summary of the α-syn species detected by MS in brain lysates from two hA30Pα-syn mice with functional parkin (column # 1–2) and three hA30Pα-syn mice lacking both parkin alleles (column # 3–5)
The α-synD135 species deposited are preferentially associated with PS129α-syn in the presence and absence of Parkin
We investigated whether α-synD135 was phosphorylated or ubiquitylated and whether there were differences in these modifications associated with Parkin deficiency, by performing double immunofluorescence staining on brain sections from symptomatic hA30Pα-syn mice with functional parkin or with no functional parkin alleles. Staining for α-synD135 was significantly less abundant than staining for PS129α-syn (Figure 5B) and ubiquitin (Figure 5C), in mice of both genotypes. Consistent with the observations in LB, most α-synD135 immunoreactivity was found to be associated with PS129α-syn-positive deposits (Figure 5B and Figure 5D, second graph from the left). However, it often did not cover the entire PS129α-syn-positive structure within a particular neuronal cell body or process, or extended beyond it (Figure 5B). The degree of colocalization within regions displaying both types of immunoreactivity was high, regardless of parkin expression status (Figure 4B, representative Pearson’s correlation coefficient: 0.9 ± 0.04). α-SynD135 and ubiquitin colocalized in some neurons, but were also observed independently of each other in approximately 50% of the neuronal cell bodies and processes in symptomatic hA30Pα-syn mice, regardless of parkin expression status (Figure 4C, representative Pearson’s correlation coefficients: 0.8 ± 0.03; Figure 5C and D, graphs on the right).
PS129α-syn accumulates as fibrillar species in symptomatic hA30Pα-syn mice with and without Parkin
This study confirms and extends our previous work showing that the loss of both parkin alleles significantly delays sensorimotor impairment related to the progression of α-synucleinopathy in hA30Pα-syn mice . We report here the results of a more complete comparative behavioral longitudinal follow-up study of hA30Pα-syn mice with two functional parkin alleles, or with the loss of one or both parkin alleles. In addition to the rotarod task and the analysis of hindlimb reflex symmetry, we used the hindlimb reflex amplitude and footprint tests to evaluate the behavior of the animals. Strikingly, this follow-up not only confirmed our previous results, but also revealed a protective effect of the loss of a single parkin allele. In addition, Parkin depletion had a clear dose-dependent effect on performance in the rotarod task, with different performance curves for hA30Pα-syn mice with two, one or no functional parkin alleles.
The loss of parkin expression delayed sensorimotor impairment in hA30Pα-syn mice, but only slightly modified neuropathological presentation in end-stage disease. The extent and intensities of the immunoreactivities against ubiquitin, PS129α-syn and α-syn truncated at D135 were generally similar in hA30Pα-syn mice with and without parkin expression. Consistent with the current hypothesis that α-syn phosphorylated at S129 plays a key role in the neuropathological process, PS129α-syn was deposited as loose fibrils throughout the brainstem and the spinal cord in affected animals only, regardless of parkin expression status. In hA30Pα-syn mice of both parkin genotypes, some of the PS129α-syn-positive deposits colocalized with immunostaining for ubiquitin or α-synD135, which were significantly less widely distributed than the PS129α-syn staining, consistent with observations in human brains affected by α-synucleinopathy. Ubiquitin and α-synD135 were mostly found concomitantly with PS129α-syn, indicating that ubiquitylation and C-terminal truncation at D135 are secondary PTM. As reported in our previous study , the proportion of PS129α-syn deposits in neuronal cell bodies associated with ubiquitin was lower in hA30Pα-syn mice lacking both parkin alleles than in hA30Pα-syn mice with functional parkin alleles, possibly indicating less advanced α-synucleinopathy. By contrast, parkin dysfunction was not associated with any significant difference in the proportion of PS129α-syn deposits costained for α-synD135, or in the degree of colocalization between α-synD135- and ubiquitin-immunoreactive protein deposits in the neuronal somata or processes of hA30Pα-syn mice. It is widely accepted that ubiquitylation is primarily associated with PS129α-syn in human α-synucleinopathies, but less is known about the crosstalk between S129 phosphorylation and C-terminal truncation. Anderson et al.  reported that all peptides corresponding to the α-synY133 fragment identified by MS were phosphorylated at S129 in LB fractions . We found that recombinant α-synY133 and α-synD135 proteins were less well phosphorylated by PLK3 than the full-length protein in vitro[37, 39], suggesting that C-terminal truncation does indeed occur once the protein has been phosphorylated. However, the partial dissociation between immunostaining for α-synD135 and that for PS129α-syn often observed in the double-labeled neuronal cell bodies and processes of hA30Pα-syn mice, regardless of parkin expression, suggests that α-syn truncation at D135 may also arise independently of phosphorylation on S129. Alternatively, there may be interference between the two types of immunohistochemical staining, due to the physical proximity of the PTM examined: it is not unlikely, for example, that a deposit of PS129α-syn with a high proportion of truncated protein is less efficiently recognized by antibodies specific for the phosphorylated species.
There is some debate about whether the ubiquitylation of α-syn constitutes a proteasomal degradation signal , but proteasome dysfunction, which is thought to occur during the progression of α-synucleinopathy [29, 40, 41], may generate C-terminally cleaved α-syn fragments [12, 42]. However, the random nature of the association between the patterns of immunostaining for ubiquitin and α-synD135 in our study is not consistent with ubiquitylation playing a role in the generation of such fragments.
Despite the mitigation of the preclinical α-syn-related phenotype revealed by our longitudinal behavioral follow-up study, the partial depletion of Parkin did not delay overt manifestation of the neurological phenotype in hA30Pα-syn mice. The lack of impact of Parkin deficiency on disease penetrance and progression reported in hA53Tα-syn mice , therefore does not exclude a moderate modifier effect, as the study concerned was based on late-stage neurological phenotypes and single-point analyses of specific behavioral measures. Alternatively, the absence of interaction between Parkin and α-synA53T may reflect different effects of Parkin deficiency on the pathological alterations caused by different α-syn variants . However, a recent in vitro study reported the rescue of cortical neurons from the harmful effects of α-synA53T toxicity by siRNA-mediated downregulation of the parkin gene, supporting the notion that there is a beneficial modifier effect associated with this condition .
In conclusion, we confirm here that Parkin depletion modifies α-syn-induced neurodegeneration in hA30Pα-syn mice. The loss of a single functional parkin allele was sufficient to delay the appearance of preclinical signs of motor dysfunction in this model, albeit to a lesser extent than observed with the loss of both alleles, with no effect on appearance of overt disease signs. An analysis of the α-syn protein deposits revealed possible interplay between PTM: ubiquitylation and truncation at D135 were associated preferentially with PS129α-syn, whereas ubiquitylation and α-synD135 were found both independently and in association. The distribution and composition of the PS129α-syn deposits were similar in the presence and absence of Parkin in the end stage of disease, suggesting that a loss of Parkin function does not fundamentally alter the nature of events leading to protein accumulation in this mouse model. A detailed quantitative investigation of the proteins, signaling and degradation pathways thought to regulate α-syn-dependent neurodegeneration during the preclinical and early symptomatic stages of the disease might shed light on the mechanisms underlying the neuroprotection associated with Parkin deficiency in future studies.
α-syn phosphorylated at S129
Mouse model producing the pathogenic human A30P variant of α-syn
- α-synD135 and α-synY133:
α-syn truncated at D135 and Y133
Human A30P variant of α-syn
Polo-like kinase 3
Sodium dodecyl sulfate
Bovine serum albumin
Newborn goat serum
This work was supported by Institut National de la Santé et de la Recherche Médicale, Fédération pour la Recherche sur le Cerveau, Fondation de France, Fondation ICM, APOPIS (an integrated project funded by the EU under the Sixth Framework Programme; Priority: Life Science for Health, contract no. LSHM-CT-2003-503330). MF and AR were supported by the French Ministry of Research. MF was also supported by the Fondation pour la Recherche Médicale, and AR by the Association France Parkinson. We thank M Moniatte, R Hamelin, D Chiappe (Proteomic Core Facility, EPFL, Lausanne) and N Jordan (Laboratory of Molecular Neurobiology and Neuroproteomics, EPFL, Lausanne) for excellent technical support. Confocal images were acquired at the Plate-forme d’Imagerie Cellulaire Pitié-Salpêtrière (Hôpital de la Pitié-Salpêtrière, Paris). hA30Pα-syn mice for breeding were kindly provided by PJ Kahle (Hertie Institute for Clinical Brain Research, Tübingen) and human tissue was provided by the GIE NeuroCEB (Hôpital de la Pitié-Salpêtrière, Paris).
- Oueslati A, Fournier M, Lashuel HA: Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res. 2010, 183: 115-145.View ArticlePubMedGoogle Scholar
- Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, et al: Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006, 281 (40): 29739-29752. 10.1074/jbc.M600933200.View ArticlePubMedGoogle Scholar
- Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T: Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002, 4 (2): 160-164.PubMedGoogle Scholar
- Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG: Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem. 2003, 278 (45): 44405-44411. 10.1074/jbc.M308041200.View ArticlePubMedGoogle Scholar
- Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, Trojanowski JQ, Mann D, Iwatsubo T: Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem. 2002, 277 (50): 49071-49076. 10.1074/jbc.M208046200.View ArticlePubMedGoogle Scholar
- Sampathu DM, Giasson BI, Pawlyk AC, Trojanowski JQ, Lee VM: Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol. 2003, 163 (1): 91-100. 10.1016/S0002-9440(10)63633-4.PubMed CentralView ArticlePubMedGoogle Scholar
- Rott R, Szargel R, Haskin J, Shani V, Shainskaya A, Manov I, Liani E, Avraham E, Engelender S: Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem. 2008, 283 (6): 3316-3328.View ArticlePubMedGoogle Scholar
- Nonaka T, Iwatsubo T, Hasegawa M: Ubiquitination of alpha-synuclein. Biochemistry. 2005, 44 (1): 361-368. 10.1021/bi0485528.View ArticlePubMedGoogle Scholar
- Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T: Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol. 1998, 152 (4): 879-884.PubMed CentralPubMedGoogle Scholar
- Campbell BC, McLean CA, Culvenor JG, Gai WP, Blumbergs PC, Jakala P, Beyreuther K, Masters CL, Li QX: The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem. 2001, 76 (1): 87-96.View ArticlePubMedGoogle Scholar
- Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, Jakala P, Hartmann T, Price DL, et al: Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A. 2005, 102 (6): 2162-2167. 10.1073/pnas.0406976102.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ: A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem. 2005, 280 (24): 22670-22678. 10.1074/jbc.M501508200.View ArticlePubMedGoogle Scholar
- Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, Feany MB: Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest. 2009, 119 (11): 3257-3265.PubMed CentralPubMedGoogle Scholar
- Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, Dawson TM: Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med. 2001, 7 (10): 1144-1150. 10.1038/nm1001-1144.View ArticlePubMedGoogle Scholar
- Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D: Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain. 2007, 130 (Pt 3): 799-815.View ArticlePubMedGoogle Scholar
- Fournier M, Vitte J, Garrigue J, Langui D, Dullin J-P, Saurini F, Hanoun N, Perez-Diaz F, Cornilleau F, Joubert C, et al: Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. PLoS One. 2009, 4 (8): e6629-10.1371/journal.pone.0006629.PubMed CentralView ArticlePubMedGoogle Scholar
- Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM: Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002, 34 (4): 521-533. 10.1016/S0896-6273(02)00682-7.View ArticlePubMedGoogle Scholar
- Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL: Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 - > Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A. 2002, 99 (13): 8968-8973. 10.1073/pnas.132197599.PubMed CentralView ArticlePubMedGoogle Scholar
- Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P: Alpha - synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A. 2002, 99 (16): 10813-10818. 10.1073/pnas.152339799.PubMed CentralView ArticlePubMedGoogle Scholar
- Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000, 287 (5456): 1265-1269. 10.1126/science.287.5456.1265.View ArticlePubMedGoogle Scholar
- Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, et al: Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest. 2002, 110 (10): 1429-1439.PubMed CentralView ArticlePubMedGoogle Scholar
- Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T: Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci. 2011, 31 (46): 16884-16894. 10.1523/JNEUROSCI.3967-11.2011.View ArticlePubMedGoogle Scholar
- van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, et al: Neuropathology in mice expressing human alpha-synuclein. J Neurosci. 2000, 20 (16): 6021-6029.PubMedGoogle Scholar
- Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H: Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem. 2004, 91 (2): 451-461. 10.1111/j.1471-4159.2004.02728.x.View ArticlePubMedGoogle Scholar
- Corti O, Lesage S, Brice A: What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev. 2011, 91 (4): 1161-1218. 10.1152/physrev.00022.2010.View ArticlePubMedGoogle Scholar
- Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, et al: Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med. 2000, 342 (21): 1560-1567. 10.1056/NEJM200005253422103.View ArticlePubMedGoogle Scholar
- Dawson TM, Dawson VL: The role of parkin in familial and sporadic Parkinson's disease. Mov Disord. 2010, 25 (Suppl 1): S32-39.PubMed CentralView ArticlePubMedGoogle Scholar
- Haywood AF, Staveley BE: Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci. 2004, 5: 14-10.1186/1471-2202-5-14.PubMed CentralView ArticlePubMedGoogle Scholar
- Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, et al: Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 2002, 36 (6): 1007-1019. 10.1016/S0896-6273(02)01125-X.View ArticlePubMedGoogle Scholar
- Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B: Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron. 2003, 37 (6): 911-924. 10.1016/S0896-6273(03)00143-0.View ArticlePubMedGoogle Scholar
- von Coelln R, Thomas B, Andrabi SA, Lim KL, Savitt JM, Saffary R, Stirling W, Bruno K, Hess EJ, Lee MK, et al: Inclusion body formation and neurodegeneration are parkin-independent in a mouse model of alpha-synucleinopathy. J Neurosci. 2006, 26 (14): 3685-3696. 10.1523/JNEUROSCI.0414-06.2006.View ArticlePubMedGoogle Scholar
- Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, et al: Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol. 2001, 159 (6): 2215-2225. 10.1016/S0002-9440(10)63072-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, et al: Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet. 2003, 12 (18): 2277-2291. 10.1093/hmg/ddg239.View ArticlePubMedGoogle Scholar
- Vitte J, Traver S, Maues De Paula A, Lesage S, Rovelli G, Corti O, Duyckaerts C, Brice A: Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol. 2010, 69 (9): 959-972. 10.1097/NEN.0b013e3181efc01c.View ArticlePubMedGoogle Scholar
- Jan C, Muriel MP, Rolland AS, Hirsch EC, Francois C: Localization of D1a dopamine receptors on cell bodies and axonal endings in the substantia nigra pars reticulata of the rat. J Neural Transm. 2007, 114 (12): 1509-1517. 10.1007/s00702-007-0775-8.View ArticlePubMedGoogle Scholar
- Thingholm TE, Larsen MR: The use of titanium dioxide micro-columns to selectively isolate phosphopeptides from proteolytic digests. Methods Mol Biol. 2009, 527: 57-66. 10.1007/978-1-60327-834-8_5. xiView ArticlePubMedGoogle Scholar
- Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, et al: Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem. 2010, 285 (4): 2807-2822. 10.1074/jbc.M109.081950.PubMed CentralView ArticlePubMedGoogle Scholar
- Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT, Fernandez CO, Eliezer D, Zweckstetter M, et al: Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem. 2008, 283 (24): 16895-16905. 10.1074/jbc.M800747200.PubMed CentralView ArticlePubMedGoogle Scholar
- Inglis KJ, Chereau D, Brigham EF, Chiou SS, Schobel S, Frigon NL, Yu M, Caccavello RJ, Nelson S, Motter R, et al: Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem. 2009, 284 (5): 2598-2602.PubMed CentralView ArticlePubMedGoogle Scholar
- Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA: Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci. 2001, 21 (24): 9549-9560.PubMedGoogle Scholar
- Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, LD V, Dawson TM, Ross CA: Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet. 2001, 10 (9): 919-926. 10.1093/hmg/10.9.919.View ArticlePubMedGoogle Scholar
- Lewis KA, Yaeger A, DeMartino GN, Thomas PJ: Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations. J Bioenerg Biomembr. 2010, 42 (1): 85-95. 10.1007/s10863-009-9258-y.PubMed CentralView ArticlePubMedGoogle Scholar
- Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, Zharkovsky A, Kaasik A: Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem. 2011, 286 (12): 10814-10824. 10.1074/jbc.M110.132514.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.